• No results found

Cover Page The handle http://hdl.handle.net/1887/3176520 holds various files of this Leiden University dissertation. Author: Rijkmans, E.C. Title: Brachytherapy for rectal cancer Issue date: 2021-06-08

N/A
N/A
Protected

Academic year: 2022

Share "Cover Page The handle http://hdl.handle.net/1887/3176520 holds various files of this Leiden University dissertation. Author: Rijkmans, E.C. Title: Brachytherapy for rectal cancer Issue date: 2021-06-08"

Copied!
6
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

Cover Page

The handle http://hdl.handle.net/1887/3176520 holds various files of this Leiden University dissertation.

Author: Rijkmans, E.C.

Title: Brachytherapy for rectal cancer

Issue date: 2021-06-08

(2)

Brachytherapy for rectal cancer

Eva Cornelia Rijkmans

(3)

Brachytherapy for rectal cancer

© Eva C. Rijkmans, 2021, Leiden, The Netherlands. All rights reserved. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any forms or by any means, without prior permission of the author.

(4)

Proefschrift

ter verkrijging van

de graad van doctor aan de Universiteit Leiden, op gezag van rector magnificus prof.dr.ir. H. Bijl, volgens besluit van het college voor promoties

te verdedigen op dinsdag 8 juni 2021 klokke 13.45 uur

door

Eva Cornelia Rijkmans geboren te Amsterdam

op 19 maart 1988

Brachytherapy for

rectal cancer

(5)

Promotores: Prof. dr. C.A.M. Marijnen

Prof. dr. R.A. Nout, Erasmus Universiteit Rotterdam Co-promotor: Dr. F.P. Peters, Antoni van Leeuwenhoek, Amsterdam Promotiecommissie: Prof. dr. C.L. Creutzberg

Prof. dr. G.L. Beets, Universiteit Maastricht Dr. M. Berbée, Universiteit Maastricht Dr. Ir. E. M. Kerkhof

(6)

CONTENTS

Chapter 1 Introduction and outline thesis 7

Chapter 2 Gastrointestinal toxicity in chemoradiotherapy for rectal cancer: 27 comparison of three bowel contouring methods and evaluation of

dose-response and risk-factors Submitted

Chapter 3 Endorectal brachytherapy boost after external beam radiotherapy in 53 elderly or medically inoperable patients with rectal cancer: Primary

outcomes of the phase I HERBERT study

International Journal of Radiation Oncology Biology and Physics 2017 Jul 15;98(4):908-917

Chapter 4 Evaluation of clinical and endoscopic toxicity after external beam 73 radiotherapy and endorectal brachytherapy in elderly patients with

rectal cancer treated in the HERBERT study Radiotherapy and Oncology 2018;126(3):417-423

Chapter 5 Predictive factors for response and toxicity after brachytherapy for 97 rectal cancer; results from the HERBERT study

Radiotherapy and oncology 2019;133:176-182

Chapter 6 Benefit of adaptive CT-based treatment planning in high-dose-rate 117 endorectal brachytherapy for rectal cancer

Brachytherapy 2018;17(1):78-85

Chapter 7 EUS-guided fiducial marker placement for radiotherapy in rectal 133 cancer: feasibility of two placement strategies and four fiducial types

Endoscopy international open 2019;7(11):E1357-e64

Chapter 8 Summary 149

Chapter 9 General discussion 155

Appendices Nederlandse samenvatting 184

List of publications 190

Author affiliations 192

Dankwoord 196

Curriculum Vitae 198

Referenties

GERELATEERDE DOCUMENTEN

3 (MvT), daaruit blijkt dat het kabinet deze legitimatie deels over heeft genomen uit het negatieve advies van de Raad van State over Wet aan- spraak op

Voor zover het maken van reprografische verveelvoudigingen uit deze uitgave is toegestaan op grond van artikel 16h Auteurswet dient men de daarvoor wettelijk verschuldigde

This study evaluated toxicity and efficacy of the combination of external beam radiotherapy (EBRT) followed by high dose rate endorectal brachytherapy (HDREBT) boost in elderly and

“Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy.” This article was published in international journal of

To evaluated toxicity and efficacy of the combination of external beam radiotherapy (EBRT) followed by high dose rate endorectal brachytherapy (HDREBT) boost in elderly

For this study, toxicity was assessed using three methods: patient reported symptoms as assessed with questionnaires, clinical proctitis scored by the treating physician according

A randomised phase 3 trial comparing atezolizumab plus bevacizumab and standard chemotherapy (carboplatin and pemetrexed) versus bevacizumab and standard chemotherapy as

A randomised phase 3 trial comparing atezolizumab plus bevacizumab and standard chemotherapy (carboplatin and pemetrexed) versus bevacizumab and standard chemotherapy as